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Abstract 
Cognitive Functioning and Physical Activity During Menopause:  
A Pilot Study 
Greer A. Raggio 
 
 
 
Background: Cognitive problems such as forgetfulness, concentration difficulty, and 
inattention are commonly reported among women in or around the menopause 
transition. However, objective neurocognitive data do not consistently corroborate 
subjective cognitive complaints, nor do they effectively distinguish women in 
different reproductive stages. Further assessments must be conducted to determine the 
specific cognitive changes occurring around the menopause transition in comparison 
to other reproductive stages (e.g., late postmenopause). Furthermore, non-
pharmacological methods for addressing reported cognitive difficulties should be 
explored. Aims: The primary study aim (Aim 1) was to evaluate cross-sectional 
differences in subjective and objective cognitive function among women in 
perimenopause (irregular menstruation to 1 year after the final menstrual period), 
early postmenopause (1-5 years after the final menstrual period) and late menopause 
(> 5 years after the final menstrual period). The secondary aim (Aim 2) was to 
compare changes in cognitive function and physical activity among women who 
completed a six-month physical activity intervention. Hypotheses: It was 
hypothesized that women in perimenopause would score lower on tests of attention 
and working memory than women in postmenopause. It was also hypothesized that 
increases in physical activity would be significantly associated with improvements on 
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attention and working memory tasks. Procedure: Forty-five women age 40 to 63 
(mean age = 53.6 years) were recruited for a six-month, group-based intervention 
designed to help midlife women increase sustained aerobic activity. Neurocognitive 
and physical activity assessments occurred at baseline and 6 months. Participants 
were given weekly exercise prescriptions, gradually working toward 250 minutes of 
MVPA per week. Measures: The following neurocognitive domains were evaluated 
using clinician-administered tests: Global cognition (MoCA) and intelligence 
(WTAR), attention and working memory (Letter N-Back computer test; Digit Span), 
verbal learning and memory (Selective Reminding Test), verbal fluency (COWA), 
and executive function (Trails A and B). Physical activity was quantified by seven-
day ActiGraph GT3X accelerometer readings. Statistical Analyses: Regression and 
ANOVA tests were performed (using the GLM procedure in SPSS), in addition to 
Pearson’s r correlations. Results: At baseline, women in early postmenopause showed 
significantly worse verbal memory performance than women in perimenopause or 
late postmenopause (p < .05), controlling for age, mood, and sleep quality. At six 
months, women in early postmenopause showed significantly greater improvement in 
immediate verbal memory than women in perimenopause (p = .048). Reproductive 
stage also significantly predicted changes in verbal fluency after controlling for 
covariates. Self-reported improvement in concentration was also significantly 
associated with improved verbal fluency scores at 6 months (p = .004). While 
physical activity was not significantly associated with changes in neurocognitive 
function at 6 months in the full sample, increases in light activity were associated 
with improvements in verbal fluency among women in perimenopause. Conclusions: 
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The results of this study suggest that the early postmenopause stage is a period of 
cognitive vulnerability, specifically with respect to verbal memory. While sustained 
aerobic activity did not have a clear impact on neurocognitive function in this 
participant sample, women in the menopause transition may find benefit from light 
activity. Women should be informed of the possibility of cognitive disruption after 
menopause, and effective behavioral methods for managing verbal difficulties should 
be identified. 
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CHAPTER 1: INTRODUCTION 
Subjective memory difficulty and forgetfulness are common in midlife, and 
some research shows particularly high rates (about 60-80%) of reported memory and 
attention problems among women in and around the “menopause transition” (i.e., 
stage of menstrual irregularity prior to the final menstrual period; Mitchell & Woods, 
2001; Schaafsma et al., 2010; Weber et al., 2012). Specific complaints include 
difficulty remembering digits (e.g., phone numbers) and words, increased need for 
memory aids, forgetting the intended purpose of a behavior (e.g., reason for leaving a 
room), inattention and distractibility, forgetting future and past events, and “losing 
one’s train of thought” (Mitchell & Woods, 2001; Schaafsma et al., 2010). These 
symptoms are associated with distress and may negatively impact perceived 
performance on daily activities (Epperson et al., 2011; Woods, Mitchell, & Adams, 
2000).  
A host of causal and correlational factors have been suggested in the literature 
to explain this phenomenon; these include natural cognitive aging, stress from family 
and work demands, disrupted sleeping patterns, weight gain, depression, and 
reproductive hormone fluctuations (Henderson, 2011; Mitchell & Woods, 2001; 
Schaafsma, Homewood, & Taylor, 2010). In addition to fluctuations in ovarian 
hormone levels, particularly estrogen, select menopausal symptoms (e.g., night 
sweats leading to sleep disruption) may also be important (Freeman et al., 2007; 
Weber, Rubin, & Maki, 2013). However, no single or specific target for intervention 
has been identified. While recent research has begun to explore the impact of the 
menopause transition on cognitive function, objective neurocognitive data have often 
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failed to corroborate subjective memory complaints. This has led many in the field to 
refute a direct relation between reproductive stage and cognitive function (Fuh et al., 
2006; Henderson et al., 2011; Kok et al., 2006; Meyer et al., 2003).  
Newer research presents a convincing argument for real and specific cognitive 
changes occurring during the menopause transition and early postmenopause. This 
study attempted to illuminate the significance of female reproductive stage on 
neurocognitive performance in multiple domains. A brief contextual review of 
menopause is first presented. This is followed by a discussion of empirical evidence 
supporting an association between reproductive stage and cognitive function, in 
addition to proposed mechanisms of action. Finally, physical activity is examined as a 
non-pharmacological approach for alleviating cognitive symptoms in this population. 
1.1 Menopause Overview 
Menopause is a point in time coinciding with a female’s final menstrual 
period, which generally occurs between the ages of 42 and 58 (National Institute on 
Aging [NIA], 2010; Soules et al., 2001). At this time, the depleted store of oocyte-
producing follicles in the ovaries causes a dramatic reduction in circulating estrogen 
and progesterone levels and, ultimately, a loss of reproductive capacity. A 
comprehensive review of the reproductive cycle is beyond the scope of this paper; 
further mention of reproductive hormones will occur in the context of menopause and 
cognition only. 
Menopause is temporally defined by the Stages of Reproductive Aging 
Workshop (STRAW) criteria, which divide the female reproductive life cycle in three 
phases: the “reproductive” phase (after the onset of menses), the “menopause 
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transition,” and “postmenopause” (Soules et al., 2001).1 Both the menopause 
transition and postmenopause are further separated into early and late stages. The 
“early transition” (Stage -2) begins with the onset of irregular menstruation, defined 
as the lengthening or shortening of the menstrual cycle by seven or more days. The 
“late transition” (Stage -1) begins after 60 consecutive days of amenorrhea (i.e., 
absence of menstruation) and ends with the final menstrual period (Stage 0). 
Altogether, the menopause transition lasts between three and seven years, on average 
(NIA, 2012). Subsequently, women enter “early postmenopause” (Stage +1), which 
spans the final menstrual period to five years later. Entry into “late postmenopause” 
(Stage +2) represents the final stage of the reproductive lifecycle. Perimenopause is 
an additional term encompassing the beginning of the menopause transition through 
the first 12 months of (early) postmenopause.  
During the menopause transition, fluctuations in estrogen, progesterone, and 
follicle-stimulating hormone (FSH) result in chronic hormone imbalances (Office of 
Women’s Health [OWH], 2010). This may generate a host of physical symptoms, 
including hot flashes (also called “flushes”), night sweats and disrupted sleep, vaginal 
changes (e.g., dryness), fatigue, aches and joint pain, weight gain, and urinary 
incontinence (Freeman et al., 2007; NIA, 2010). Emotional and psychosocial 
complaints related to the menopause transition are also common. Dysregulated mood 
(e.g., crying, mood swings, irritability), decreased interest in sex, a disrupted sense of 
femininity, and depression are perhaps most notable (OWH, 2010). Cognitive 
                                                        
 
1 STRAW criteria pertain only to healthy women who experience natural reproductive aging. They do 
not apply to individuals with atypical reproductive anatomy or a history of menstrual cycle irregularity, 
elite athletes, or smokers (Soules et al., 2001). 
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problems such as forgetfulness and lack of concentration are also quite common, as 
previously noted.  
1.2 Menopause and Cognitive Function 
Research efforts have frequently failed to uncover a direct link between 
menopause and self-reported cognitive deficits, and perceived impairments have 
historically been attributed to natural aging or mood alteration (Fuh et al., 2003; 
Schaafsma et al., 2010). In fact, some studies have shown longitudinal improvements 
in verbal fluency (i.e., the ability to generate verbal information based on specific 
parameters) test scores among perimenopausal women (Fuh et al., 2006; Meyer et al., 
2003). Several explanations for these findings are posited. First, practice effects (i.e., 
improvement on test scores due to practice), particularly on less challenging 
neurocognitive tasks, may mask subtle deficits (Weber et al., 2013). Care must 
therefore be taken in selecting sensitive and psychometrically sound measures. 
Additionally, many studies have failed to evaluate the full range of cognitive 
domains; testing has focused on short-term memory to the exclusion of other relevant 
cognitive processes such as thinking, reaction speed, and attention (Schaafsma et al., 
2010). However, newer evidence emerging from comprehensive assessments of 
neurocognitive function generally supports an association between menopause and 
cognitive problems.  
Weber & Mapstone (2009) presented compelling evidence for an association 
between subjective memory complaints and performance on clinician-administered 
tasks of attention, encoding, verbal fluency, and working memory among 
perimenopausal females (age 40-57). Those reporting memory problems were also 
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more likely to endorse mood disturbance and somatic symptoms; however, mood 
alone did not account for the observed memory deficits. These findings were later 
replicated in a larger participant sample by the same research team (Weber et al., 
2012). Furthermore, perimenopausal participants in this study demonstrated objective 
deficits in verbal memory compared with age-based test norms.   
The Study of Women’s Health Across the Nation (SWAN), an observational 
evaluation of 2,362 midlife females, showed that reproductive stage (and not age) 
influenced longitudinal changes in cognitive scores (Greendale et al., 2009). 
Specifically, women in perimenopause showed significantly less four-year 
improvement on measures of processing speed and verbal episodic memory compared 
to women in premenopause or postmenopause (Greendale et al., 2009). Another study 
found that women in early postmenopause (within 12 months of final menstrual 
period, i.e., late perimenopause) performed worse on tasks of attention and working 
memory compared with participants in the late menopause transition (Weber, Rubin 
& Maki, 2013). More recently, Berent-Spillson and colleagues (2012) found 
decreased verbal fluency among women in the menopause transition compared to 
women in premenopause and postmenopause. Together, these findings suggest a 
relative disadvantage in cognitive capacity during perimenopause.  
 1.2.1 Possible mechanism of action: estrogen. 
The reduction in and fluctuation of estrogen during menopause has been 
postulated as the source of observed disruptions in executive function, attentional 
processes, and memory (Keenan, Ezzat, Ginsburg, & Moore, 2001). To review, 
endogenous estrogen minimizes cell death in conditions of deprivation and toxicity, 
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stimulates neuronal growth, and promotes repair of damaged neural structures (Behl 
et al., 2002; McEwen & Alves, 1999). Brain regions that are rich in estrogen 
receptors (and therefore support estrogen-mediated cognitive processes) include the 
hippocampus, which is responsible for the consolidation of short-term memory, and 
the prefrontal cortex, which governs executive function processes such as planning, 
working memory, task coordination, and selective filtering (i.e., concentration amidst 
distraction; Behl et al., 2002; Keenan et al., 2001). Preclinical experiments in rats and 
non-human primates demonstrate cognitive benefits in response to estrogen treatment 
with and without progesterone (Inagaki et al., 2010; Rapp et al., 2003; Shanmugan & 
Epperson, 2012). Estrogen also results in higher concentrations of metabolites in the 
rat prefrontal cortex, indicating enhanced executive function (Inagaki et al., 2010). 
In humans, estrogen appears to facilitate verbal fluency and articulation, in 
addition to perceptual speed. To illustrate, women frequently perform better on tests 
of verbal fluency during high-estrogen points in the menstrual cycle (Kimura & 
Hampson, 1994). Neural imaging data corroborate these findings, as activity in the 
prefrontal cortex changes in parallel with the menstrual cycle (Shanmugan & 
Epperson, 2012). Furthermore, Berent-Spillson and colleagues (2012) showed 
correlations between regional brain activation and estradiol levels among women 
performing a verbal fluency task. These findings support a hypothesis that alterations 
in circulating estrogen levels may impact executive function and verbal memory.  
By extension, it has been suggested that the use of menopausal hormone 
therapy may impact cognitive function. However, the specific effects of these 
treatments on cognitive-affective symptoms are inconsistent across studies 
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(Greendale et al., 1998; Mitchell & Woods, 2001; Rapp et al., 2003; Shumaker et al., 
2004). The Seattle Midlife Women’s Health Study found that poor self-reported recall 
of numbers and words was more prevalent among perimenopausal and 
postmenopausal women not using menopausal hormone therapy, while behavioral 
forgetfulness (e.g., misplacing items) was more common in hormone users (Mitchell 
& Woods, 2001). Age may also moderate the efficacy of hormone treatment; the 
Women’s Health Initiative Memory Study found that individuals who initiated 
menopausal hormone therapy after age 65 were at increased risk for dementia 
(Shumaker et al., 2004). Potential explanations for these inconsistencies include 
differences across hormone treatments (e.g., dose, formulae) and timing of treatment 
initiation (Shanmugan & Epperson, 2012). In sum, the existing evidence does not 
support a clear causal effect between hormone use and cognitive dysfunction. 
1.2.2 Possible indirect mechanisms of action.  
Weight gain and sleep disruption are common during the menopause 
transition and postmenopause, and each has been independently associated with 
cognitive function in the broader adult literature. Among male and female adults, 
overweight and obesity (independent of age) has specifically been linked to poorer 
executive function, verbal fluency, and prospective memory, in addition to increased 
risk for Alzheimer’s disease and brain atrophy when compared with normal weight 
(Gunstad et al., 2010; Gunstad et al., 2007; Gustafson, Lissner, Bengtsson, 
Björkelund, & Skoog, 2004; Krivipelto et al., 2005). It is believed that the vascular 
and metabolic risk factors (e.g., diabetes, poor cardiovascular fitness) associated with 
obesity may be responsible for these findings, though some studies have found 
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significant effects of obesity on neurocognitive function independent of comorbid 
medical conditions (Elias, Elias, Sullivan, Wolf, & D’Agostino, 2003; Gunstad et al., 
2007). In contrast, greater waist circumference has been associated with better 
performance on tests of attention, specifically Trail Making Test A, and visuospatial 
function (Gunstad et al., 2010). These findings are puzzling, given that attention and 
executive function are both governed by the prefrontal cortex. Thus, the independent 
effects of obesity on neurocognitive function remain unclear. 
In contrast, the extant literature shows clear causal relationships between sleep 
disturbance and worse cognitive function. Compared with controls, individuals with 
insomnia, obstructive sleep apnea, and self-reported disruptions in sleep duration 
have demonstrated poorer global cognitive function, attention, verbal fluency, and 
higher-level reasoning based on objective neurocognitive tests and self-report (Ferrie 
et al., 2011; Kronholm et al., 2009; Mathieu et al., 2008). Furthermore, disordered 
sleep has significantly predicted later cognitive impairment in the elderly (Vendette et 
al., 2007; Yaffe et al., 2011). Proposed mediators of these relationships include 
hypoxia (i.e., insufficient oxygen intake), alterations in metabolic and endocrine 
factors, underlying disease processes, and cardiovascular factors, among others 
(Spiegel, Leproult, & Van Cauter, 1999; Yaffe et al., 2011). While the deleterious 
clinical effects of poor sleep are well-defined, research has not shown significant 
differences in sleep quality based on reproductive stage and independent of age 
(Berent-Spillson, 2012).  
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1.3 Physical Activity and Cognitive Function 
1.3.1 Clinical and neural effects. 
An extensive body of research illustrates the benefits of physical activity on 
cognitive function in a variety of clinical and nonclinical populations. A meta-
analysis of 18 randomized controlled studies of middle-aged and older adults (≥ 55 
years) found that participants in the exercise groups scored higher on tasks of 
executive-control, speed, and visuospatial ability (Colcombe & Kramer, 2003). 
Improvements were greatest among women and for executive-control functions, such 
as planning and working memory. These findings suggest that increased 
cardiovascular fitness may influence neural activation processes and offset the natural 
deterioration associated with aging. Furthermore, that women benefitted more than 
men in these studies indicates a gender-based mechanistic difference that is not 
currently understood (Garcia-Segura et al., 2000). Other research has corroborated 
these findings and highlighted a positive linear relationship between physical activity 
and performance on verbal memory, attention, and verbal (category) fluency among 
older adult females (Weuve et al., 2004).  
Physical activity has also been used to prevent and slow the progression of 
cognitive decline associated with Alzheimer’s disease and dementia. In a longitudinal 
study of 1,740 older adults (> 65 years), those who exercised more than three times 
per week at baseline were one-third less likely to be diagnosed with dementia six 
years later compared with participants who exercised at a lower frequency (Larson et 
al., 2006). Adults with early forms of dementia have also demonstrated cognitive 
improvements in conjunction with increased exercise (Kramer & Erickson, 2007).  
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Specific neural effects from physical activity also have been observed in both 
human and animal research. In rat models, exercise enhances neural cell proliferation 
(i.e., neurogenesis) and capillary development in various brain regions, and has even 
reversed the effects of aging on neural plasticity (Swain et al., 2003; Van Praag, 
Kempermann, & Gage, 1999; Van Praag et al., 2005). These changes have been 
observed within 30 days of exercise initiation. Rats have also demonstrated improved 
performance on the Morris water navigation task in response to physical activity, 
indicating enhanced spatial learning capabilities (Adlard et al., 2004). Among human 
participants, Colcombe and colleagues (2004) observed fMRI brain activation 
patterns in older adults randomized to an aerobic exercise intervention; these 
activation patterns were comparable to those of younger individuals. Participants who 
engaged in stretching and toning exercises but no aerobic activity, however, did not 
demonstrate such patterns.  
1.3.2 Application to midlife women. 
Given the body of evidence reviewed above, there is reason to evaluate 
physical activity as a potential non-pharmacological treatment for cognitive problems 
around the menopause transition. Notably, fewer than half of American women age 
45 to 64 get the recommended amount of activity (150 minutes of moderate-intensity 
activity per week), and this percentage steadily declines with increasing age 
(Schoenborn, Adams, & Peregoy, 2013). Numerous studies have employed physical 
activity in menopause-age women to address vasomotor and mood symptoms (Carels, 
Berger, & Darby, 2006; Daley, Stokes-Lampard, & MacArthur, 2009; McAndrew et 
al., 2009); however, few have examined potential cognitive benefits. In a cross-
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sectional analysis of Australian women around menopause, Slaven & Lee (1997) 
found that those who engaged in regular aerobic activity (≥ 60 minutes weekly) were 
less likely to report problems with memory and concentration. Another randomized 
controlled trial reported a relative decrease in memory problems among exercisers 
versus non-exercising controls, though the trend did not reach significance (Aiello et 
al., 2004). No objective measures of memory were employed in these studies. The 
extent and type of cognitive improvements associated with physical activity, 
therefore, are currently unknown. 
1.4 Study Aims and Hypotheses 
 The present paper builds on the existing literature, which is primarily cross-
sectional and lacking in comprehensiveness, with a longitudinal neurocognitive 
evaluation of perimenopausal and postmenopausal women enrolled in a six-month 
physical activity intervention. All participants underwent clinician-administered 
neurocognitive tests of global cognition, attention and working memory, verbal 
learning and memory, verbal fluency, and executive function at baseline and 6 
months. Physical activity was quantified by seven-day ActiGraph GT3X 
accelerometer readings. Self-report questionnaires measuring subjective memory 
function, depression, sleep quality, menopausal symptoms, and overall health were 
also completed.  
The primary study aim (Aim 1) was to evaluate baseline differences in 
objective cognitive function across three reproductive stages: perimenopause 
(irregular menstruation to 1 year after the final menstrual period), early 
postmenopause (1-5 years after the final menstrual period) and late menopause (> 5 
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years after the final menstrual period). (Note: “early postmenopause” is defined as 
such to avoid temporal overlap with perimenopause). Analyses controlled for age, 
body mass index (BMI), depressive symptoms, and reported sleep problems, where 
appropriate. It was hypothesized that participants in perimenopause would 
demonstrate significantly poorer cognitive function compared with either 
postmenopause group. Specifically, women in perimenopause were expected to 
perform worse on attention and working memory compared with postmenopausal 
women. Additional analyses investigated differences in physical activity level and 
menopausal symptoms across groups. 
The second aim (Aim 2) was to evaluate parallel changes in cognitive function 
and physical activity over the six-month intervention period. Changes in 
neurocognitive test scores were compared with changes in accelerometer-measured 
physical activity between baseline and 6 months. Changes in neurocognitive scores, 
physical activity, and menopause symptoms were also compared across reproductive 
groups. It was hypothesized that increases in physical activity would be associated 
with improvements in cognitive function at 6 months. Given the scarcity of research 
in this area, no specific cognitive domain was expected to improve more than others.  
To this writer’s knowledge, no published study has evaluated both subjective 
and objective cognitive change in midlife women within the framework of a physical 
activity intervention. This study sought to replicate previous empirical data 
demonstrating differences in cognitive function across reproductive stages and, 
furthermore, to determine the potential efficacy of physical activity in improving 
cognitive function among midlife women. The findings may also illuminate the 
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specific window during the broader menopause years in which increased physical 
activity may be most effective.  
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CHAPTER 2: METHOD 
2.1. Recruitment 
Potential participants were midlife women enrolled in a parent pilot study for 
physical activity promotion conducted at Drexel University during late 2013 and 
early 2014 (Butryn, Arigo, Raggio, Colasanti, & Forman, 2014). The recruitment 
message advertised a brief intervention for sedentary (or not highly active) midlife 
women who wanted to increase their physical activity. Recruitment mechanisms 
included local newspapers, radio announcements, postcards, and clinic referral. 
Interested individuals were screened by phone to assess preliminary eligibility and 
provide a broad overview of study requirements. Those who appeared eligible were 
invited to attend two separate clinic visits. During the first visit (i.e., pre-baseline), 
eligibility was verified, informed consent was obtained, self-report measures were 
completed, and BMI was calculated using a standardized Seca® scale calibrated to 
0.01kg. Participants were provided with an activity sensor (i.e., accelerometer) and 
instructed to wear it for seven consecutive days after the pre-baseline visit. At the 
second visit (i.e., baseline), participants returned the loaned accelerometers and 
underwent neurocognitive testing (described below). Individuals who remained 
eligible throughout this process were enrolled for treatment. If all requirements were 
met, participants were compensated with $10 at baseline and $25 at 6 months.  
2.2 Inclusion and Exclusion Criteria 
All participants were required to meet the following inclusion criteria for 
study enrollment: (1) Age 40 to 65 years, (2) intact uterus, and (3) at least one ovary. 
Individuals screening positive for any of the following exclusion criteria were 
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deemed ineligible: (1) Unable or unwilling to engage in at least 30 min/week of 
moderate exercise (e.g., brisk walking), (2) currently engaging in ≥ 150 min/week of 
moderate-to-vigorous physical activity (MVPA), (3) planning to relocate from the 
Philadelphia area in the next three months, (4) currently pregnant or planning to 
become pregnant, (5) history of surgical menopause, (6) self-reported history of 
stroke or neurological disease (e.g., Parkinson’s), or (7) history of serious mental 
illness (e.g., psychosis).  
2.3 Intervention 
The intervention consisted of 12 group meetings (90 min each) held over the 
course of six months. Doctoral level clinicians with experience administering group 
therapy in the domains of exercise promotion and weight control delivered the 
treatment. All participants were divided evenly into three groups, and all received the 
same intervention. Sessions focused on strategies for increasing and maintaining a 
high level of physical activity, with a focus on moderate-to-vigorous physical activity 
in bouts of 10 minutes or more (MVPA-10), using behavioral principles such as 
planning, problem solving, self-monitoring, and constructing and executing a reward 
system. Participants were expected to track their physical activity (day, time, 
duration, type) and provide an activity report at the start of each group meeting. A 
lesser percentage of group time (about 30%) was devoted to healthy eating strategies 
and other relevant topics (e.g., stress management). All material was adapted to the 
participant demographic to ensure relevance and enhance impact (e.g., the negative 
consequences of menopausal symptoms on physical wellbeing and sleep quality were 
discussed as barriers to exercise). Participants were provided with weekly exercise 
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prescriptions, gradually working toward 250 min/week of moderate-to-vigorous 
physical activity (MVPA), as recommended by the American College of Sports 
Medicine (Donnelly et al., 2009). Group sessions were audio-recorded for 
supervisory purposes and to ensure protocol fidelity.  
Assessments were conducted at baseline and 6 months. Visits were held at the 
laboratory clinic and lasted approximately 60 minutes. All data were de-identified, 
password-protected, and stored in a secure electronic shared drive designated 
exclusively for the Drexel University Department of Psychology. 
2.4 Measures  
 Unless otherwise noted, all measures were administered at both baseline and 6 
months.    
2.4.1 Global cognitive function and intelligence. 
Montreal Cognitive Assessment (MoCA).  A common 11-item screening tool 
for mild cognitive dysfunction (Nasreddine et al., 2005). The MoCA assesses a 
number of cognitive domains, including attention and concentration, executive 
function, memory, language, visuoconstructional skills, conceptual thinking, 
calculations, and orientation. Scores range from 0 to 30. The MoCA has shown good 
test-retest and inter-rater reliability, and has higher sensitivity and specificity than the 
more commonly used Mini-Mental State Examination (MMSE; Gill, Freshman, 
Blender, & Ravina, 2008; Nasreddine et al., 2005). For the present study, age- and 
education-adjusted norms were applied (Rosetti, Lacritz, Cullum, & Weiner, 2011). 
The MoCA was administered at the pre-baseline visit only. 
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Wechsler Test of Adult Reading (WTAR).  A common test of reading ability, 
in which the participant is asked to pronounce 50 irregularly spelled words 
(Wechsler, 2001). Raw scores may be converted to estimated IQ scores to gauge 
overall intellectual functioning; accordingly, the WTAR has shown high correlations 
with verbal scores on intellectual tests (e.g., WAIS-III VIQ; Strauss, Sherman, & 
Spreen, 2006). The measure has also demonstrated very good test-retest reliability 
and excellent internal consistency in a variety of patient populations and in healthy 
adults (Strauss et al., 2006). For the present study, age-adjusted WTAR norms were 
applied. The WTAR was administered at the pre-baseline visit only. 
2.4.2 Verbal learning and memory. 
Buschke Selective Reminding Test (SRT).  A test of verbal learning and 
memory in which the participant must recall a list of 12 words (Buschke, 1973). The 
version used in the present study consists of up to 6 immediate recall/learning trials, 
immediate cued recall tests, an immediate recognition test, and a 30-minute delayed 
recall test. During the learning trials, the participant is reminded only of the words not 
correctly recalled. For the present study, scores were generated based on: the total 
number of words correctly recalled during learning trials (immediate recall, SRT-i), 
the number of words correctly recalled after a 30-minute delay (delayed recall, SRT-
d), the number of times words that entered long-term memory (i.e., recalled at least 
two consecutive times) were recalled (long-term retrieval, SRT-lt), and the number of 
times words that entered long-term memory were recalled consistently (i.e., at least 
three consecutive times; consistent long-term retrieval, SRT-c). The SRT has shown 
modest correlations with other more common verbal memory tests (e.g., CVLT, 
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WMS; Macartney-Filgate & Vriezen, 1988) and is a clinically useful tool for 
distinguishing normal adults from those with preclinical signs of dementia (Masur et 
al., 1989). In the present study, two validated SRT forms were used (form 1 at 
baseline, form 4 at 6 months) to minimize practice effects, and age-adjusted norms 
were applied to all subscales except SRT-d (Larrabee et al., 2000). 
2.4.3 Attention and working memory. 
Digit Span (DGT).  The Digit Span subtest of the Wechsler Adult Intelligence 
Scale–Fourth Edition (WAIS-IV) assess the ability to recall and repeat number 
sequences of increasing length (Wechsler, 2008). Participants are verbally presented 
with a series of digits (e.g., 7, 5, 2) and asked to repeat it in forward (DGT-F), 
backward (DGT-B), or ascending order (DGT-S). A single score can be generated 
based on the length of the longest series correctly recalled in each subtest. For the 
present study, WAIS-IV norms (adjusted for age) were applied. 
Letter-N-Back.  A computer task in which participants attend to flashing 
letters on the screen, and select (by pressing the spacebar) the letter that matches a 
previous letter N (0, 1, or 2) steps prior. The task requires 10-15 minutes to complete. 
2.4.4 Verbal fluency. 
Controlled Oral Word Association Test (COWA).  A test of verbal fluency in 
which participants name as many words as possible beginning with the letters “F,” 
“A,” and “S” during three, 60-second intervals (Benton & Hamsher, 1976). The 
COWA (FAS) has shown high internal reliability (Tombaugh et al., 1999) and test-
retest reliability (Ross, 2003). For the present study, Heaton norms (adjusted for 
gender, age, race, and education) were applied (Heaton et al., 2004).  
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2.4.5 Executive function. 
Trail Making Tests (TMT) Parts A and B.  Tests of processing speed and 
executive function, in addition to mental flexibility, scanning, and visual search speed 
(Reitan, 1958). Following a brief practice round, participants are asked to connect 25 
dots, either in number (Part A) or number and letter (Part B) format, in consecutive 
order. The TMT is scored based on the number of seconds required to complete each 
task. Test-retest reliability over 11 months in normal adults has been satisfactory for 
Part A and excellent for Part B; importantly, practice effects are generally minimal 
after longer periods (e.g. 9 months; Dikmen et al., 1999). For the present study, 
Heaton norms (adjusted for gender, age, race, and education) were applied (Heaton et 
al., 2004).  
2.4.6 Physical activity. 
Physical activity was measured using ActiGraph GT3X tri-axial, solid-state 
accelerometers. Tri-axial accelerometers track movement, quantify activity intensity, 
and estimate energy expenditure. The combination of measurements generates a more 
comprehensive and accurate activity profile compared with other assessment 
methods, such as pedometers or self-report (Westerterp, 2009). Participants were 
asked to wear the device for seven consecutive days; individuals who provided less 
than four days of valid accelerometer data were asked to wear the device for an 
additional seven days, or the data were excluded from analyses. Standardized 
cutpoints based on step counts (which approximate energy expenditure) were applied 
to distinguish sedentary, light, moderate, and vigorous activity; for example, 2,020 
counts/min constituted moderate-intensity activity (Troiano et al., 2008). For the 
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present study, moderate-to-vigorous physical activity (MVPA) data is presented in 
two ways: (1) total time spent in MVPA per week, and (2) total time spent in MVPA 
in bouts of 10 minutes or more (MVPA-10). Because of the known cardiovascular 
benefits associated with sustained aerobic exercise, MVPA-10 was the primary target 
of the group intervention. 
2.4.7 Self-report measures. 
Demographic data included age, race/ethnicity, marital status, household 
income, number of children, and employment status. Self-reported clinical data 
included menstrual irregularity (y/n), time since final menstruation (if applicable), 
relevant medical history (e.g., ovarian/uterine disease or surgery, neurological 
disease), use of menopausal hormone therapy, smoking status, and current 
medications. 
Memory Functioning Questionnaire (MFQ).  A 64-item survey of subjective 
memory function (Gilewski & Zelinski, 1988). Items are scored on a 7-point Likert 
scale, with higher scores indicating better memory function. Four memory domains 
are evaluated: Frequency of Forgetting, Seriousness of Forgetting, Retrospective 
Functioning, and Mnemonics Usage. Total and domain scores are obtained by 
calculating an average across items. While intended for both the baseline and 6 month 
visits, this measure was only administered at 6 months due to miscommunication with 
the project coordinator. 
Women’s Health Questionnaire (WHQ).  A 36-item survey of physical and 
emotional health (Hunter, 1992; Hunter, 2003). The measure contains nine health-
related domains: (1) somatic symptoms, (2) vasomotor symptoms, (3) sexual 
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behavior, (4) sleep problems, (5) menstrual symptoms, (6) attractiveness, (7) 
depressed mood, (8) anxiety/fears, and (9) memory/concentration. Items are summed 
by subscale and converted to T scores. Higher T scores indicate fewer problematic 
symptoms and better health. While intended for both the baseline and 6 month visits, 
this measure was only administered at 6 months due to miscommunication with the 
project coordinator. 
Beck Depression Inventory – Second Edition (BDI-II):  Assesses 21 
symptoms of depression endorsed over the previous two weeks (Beck, Steer, & 
Brown, 1996). Items are rated on a 4-point scale and summed to yield a total score. 
Scores range from 0 to 63, with higher scores indicating more severe depression. A 
score of 20 or above suggests moderate-to-severe depression, while scores above 13 
suggest at least mild depression. 
2.5 Data Analytic Strategy 
 All data were analyzed using SPSS Statistics 22.0. Raw neurocognitive data 
were translated to T scores normed for gender, age, education, and/or race. Normed 
data were used in all analyses. 
 2.5.1 Power analysis. 
Two formal a priori power analyses were conducted using the G*Power 3.1 
program (Faul et al., 2007). Using three groups and two covariates, Analysis 1 
indicated that a sample of 158 participants would allow 80% power to detect a 
medium effect size (f = .25, α = .05). Using the same specifications but a larger effect 
size, Analysis 2 indicated that a sample of 64 participants would allow 80% power to 
detect a medium-to-large effect size (f = .40, α = .05). Due to monetary and time 
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constraints, only 38 participants were recruited for the intervention; this represents a 
limitation to statistical analyses, and data interpretation should be done with caution. 
2.5 2 Statistical analyses.   
Frequency and descriptive statistics were performed on demographic, clinical 
(e.g., BMI, menopause symptoms), physical activity, and neurocognitive data. 
Pearson’s r correlations were performed to assess potential associations across key 
variables at baseline. The GLM procedure was used for all comparisons across 
reproductive groups, in addition to the within-person and mixed design (within-
between person) analyses described below. 
To address Aim 1, univariate tests compared normed neurocognitive scores 
(MoCA, WTAR, Trails A, Trails B, Digit Span, SRT, COWA) across the three 
reproductive groups (perimenopause, early postmenopause, late postmenopause) at 
baseline. Separate analyses were also done on physical activity and menopausal 
symptom data. Based on these results, multivariate tests were then performed to 
assess the influence of potential confounding factors (BMI, depression, and subjective 
sleep disturbance) in the relationships of interest.  
 To address Aim 2, six-month changes in physical activity (MVPA, MVPA-10, 
light activity, and sedentary activity) and normed neurocognitive scores (Trails A, 
Trails B, Digit Span, SRT, COWA) were compared using Pearson’s r correlations, 
and changes in reported menopausal symptoms were compared across reproductive 
groups using Fisher’s Exact tests. Repeated-measures ANOVA analyses were also 
performed to test physical activity (baseline and six-month change scores, separately) 
as a predictor of within-person changes in neurocognitive function. Additional 
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repeated-measures ANOVA analyses examined whether six-month improvements in 
concentration (y/n) predicted six-month changes in physical activity and 
neurocognitive function. Finally, six-month changes in neurocognitive function were 
compared across reproductive groups using repeated-measures ANOVA and 
ANCOVA analyses, the latter controlling for age, BMI, depression, and intellectual 
function (WTAR). 
 2.5.3 Assumption testing. 
Distributions of outcome variables and postulated correlates were examined 
for normality and outliers using histograms, stem-and-leaf plots, boxplots, and 
skewness ratios. A distribution was considered non-normal if the skewness statistic 
exceeded twice its standard error, > 2(SEskew). A data point was considered an 
extreme outlier if it exceeded 2.5 standard deviations of the mean, >2.5(SD).  Non-
normal data were first removed of extreme outliers; if the distribution remained non-
normal, it was then log-transformed.  
Examination of the primary variables of interest revealed six non-normal 
distributions at baseline (BDI-II, WTAR, Trails A, Trails B, COWA, Digit Span) and 
one non-normal distribution at 6 months (MVPA-10). Fourteen extreme outliers were 
identified and removed. Log transformations were performed on two baseline 
distributions (Trails A, Trails B) and MVPA-10 at 6 months, which successfully 
achieved normality for these distributions.  
 Tests for homogeneity of variance, normality, and extreme outliers were 
performed on regression and ANOVA analyses. Levene’s statistic was used to 
determine homogeneity of variance, where a significant Levene’s (p < .05) indicated 
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inequality of variance. Descriptives and histograms on error residuals were examined 
to identify extreme outliers and non-normality.  
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CHAPTER 3: RESULTS 
3.1 Sample Size 
A flow chart illustrating the recruitment process and participant attrition is 
presented in Figure 1. A total of 59 women provided pre-baseline survey data and. 
Forty-five of these individuals went on to complete baseline neurocognitive 
assessments. Of these individuals, seven were excluded from physical activity (PA) 
analyses due to invalid baseline accelerometer data, leaving a sample of 38 
intervention initiators. For baseline analyses across reproductive groups 
(perimenopause, early postmenopause, late postmenopause), five participants did not 
provide sufficient information to determine reproductive status, and women in 
premenopause (n = 3) were not included, leaving a sample of 37. Twenty-six women 
completed the intervention and provided valid accelerometer data. Of note, changes 
in funding for the parent pilot study restricted the recruitment sample; thus, the effect 
sizes generated by the data analyses were examined closely in light of low statistical 
power.  
3.2 Participant Characteristics and Clinical Data at Baseline 
3.2.1 Demographic characteristics. 
Baseline demographic characteristics are presented in Table 1. Participants 
ranged in age from 40 to 63 years (mean = 53.6, SD = 6.6), and 67% self-identified as 
White/Caucasian. Just over half (51%) of participants were married, and 71% 
reported having at least one child. Participants reported between 12 and 18 years of 
formal education (mean = 15.7, SD = 1.6). All adult reproductive stages were 
represented in the sample, with 7.5% in premenopause (n = 3), 35% in perimenopause 
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(n = 14), 25% in early postmenopause (n = 10), and 32.5% in late postmenopause (n 
= 13). As expected, there were significant differences in age across the three main 
reproductive groups (F[2,34] = 21.76, p < .001, ηp2 = .561); the mean age was 48.5 
years (SD = 4.1) in perimenopausal women, 54.6 years (SD = 6.4) in early 
postmenopausal women, and 59.7 years (SD = 2.8) in late postmenopausal women. 
No other significant demographic differences across the reproductive groups were 
observed.  
3.2.2 Neurocognitive scores in the full sample.  
Average baseline neurocognitive scores are presented in Table 2. Participants 
collectively performed in the average to high-average range (50th – 80th percentile) on 
all tests except immediate verbal recall (SRT-i), long-term retrieval (SRT-lt; data not 
shown), and consistent long-term retrieval (SRT-c; data not shown), which were in 
the low-average range (T < 40, or 9th to 14th percentile). Global cognitive function 
(MoCA) and intellectual function (WTAR) were in high-average range (T = 57, or 
75th percentile; and T = 58, or 80th percentile, respectively). Participants scored in the 
average range on tests of verbal fluency (COWA, T = 53 or 60th percentile), 
attention/working memory (Digit Span, T = 51 or 55th percentile), and executive 
function (Trails A, T = 51 or 55th percentile; Trails B, T = 53 or 60th percentile). Of 
note, appropriate norms were not available for delayed verbal recall and, therefore, 
percentile scores for this subscale could not be calculated. 
3.2.3 Menopausal symptoms and physical activity in the full sample. 
Baseline clinical characteristics are presented in Table 1. Eleven percent (n = 
5) of participants reported previously taking menopausal hormone therapy, and only 
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one woman reported taking it at study entry. Many participants endorsed symptoms 
characteristic of the menopause transition, including fatigue (64%), hot flashes 
(61%), headaches (48%), and night sweats (39%). Seventy percent of women 
reported having sleep problems in the prior six months; accordingly, 75% of 
participants with valid PSQI data scored above the clinical cutoff of five, indicating 
poor sleep quality. About half of the sample (51%) noted mood changes over the 
prior six months, but only four women (10%) reported symptoms consistent with 
mild to severe depression (BDI-II > 13) at baseline. Twenty-four percent  (n = 11) 
reported a history of miscarriage or fertility problems, and only one participant was a 
self-identified smoker.   
Participants spent an average of 175.23 min/week (about 25 min/day; SD = 
85.43) in moderate-to-vigorous physical activity (MVPA) and 28.11 min/week (SD = 
39.03) in MVPA bouts of 10 minutes or more (MVPA-10). The mean time spent in 
light activity and sedentary activity was 1,023.26 min/week (about 2.5 hr/day; SD = 
320.58) and 3,760.96 min/week (about 9 hr/day; SD = 1,121.54), respectively.  
3.2.4 Associations among key variables. 
Baseline Pearson’s r correlations are presented in Table 3. Higher BMI was 
significantly correlated with lower global cognitive function (MoCA; r = -.384, p = 
.019) and intellectual functioning (WTAR; r = -.544, p = .001), in addition to fewer 
MVPA min/week (r = -.474, p = .003). There was a borderline significant association 
between higher BMI and less light activity (r = -.324, p = .051). Greater weekly 
MVPA was significantly correlated with higher scores on the WTAR (r = .363, p = 
.030), and better performance on Trails A (r = .341, p = .049), and light activity was 
 
28
significantly and positively correlated with scores on Trails A (r = .576, p < .001). 
Depression (BDI-II), sleep quality (PSQI), and sedentary activity at baseline were not 
significantly associated with neurocognitive performance, including verbal 
learning/memory subscales not displayed in Table 3 (long-term retrieval and 
consistent long-term retrieval). However, higher (i.e., worse) scores on the PSQI were 
significantly correlated with greater time spent in light activity (r = .422, p = .032) 
and sedentary activity (r = .407, p = .039). Age was not significantly associated with 
any physical activity measure (data not shown). Self-reported menopause symptoms 
(i.e., fatigue, hot flashes, insomnia, night sweats, mood swings, headaches) were not 
significantly associated with scores on any neurocognitive test at baseline (data not 
shown). 
3.3 Comparisons Across Reproductive Groups at Baseline 
 3.3.1 Neurocognitive scores by reproductive group.  
Baseline raw and adjusted neurocognitive scores for each reproductive group 
are presented in Table 2. Normed scores on immediate verbal recall (SRT-i) and long-
tern verbal retrieval (SRT-lt) were significantly different across groups (SRT-i, 
F[2,34] = 3.93, p = .029, ηp2 = .193; SRT-lt, F[2,35] = 3.86, p = .031, ηp2 = .190); 
post-hoc tests showed that scores among women in early postmenopause were 
significantly worse than scores among both women in perimenopause and late 
postmenopause on both subscales (p < .05). After controlling for baseline BMI, 
depression, and reported insomnia, the difference across groups remained statistically 
significant (SRT-i, F[2,25] = 6.65, p = .006, ηp2 = .377; SRT-lt, F[2,26] = 4.85, p = 
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.019, ηp2 = .326). Scores on all remaining measures reflected nonsignificant 
differences across groups.   
3.3.2 Menopause symptoms and physical activity by reproductive group. 
Women in perimenopause were most likely to report mood changes (65%; 
Fisher’s Exact = 10.57, p = .006) and fatigue (52%; Fisher’s Exact = 7.28, p = .027) 
in the previous six months than women in early or late postmenopause. No other 
significant differences in menopause-related symptoms emerged at baseline. Of note, 
the average BMI across the full sample was 32.7 kg/m2 (SD = 7.3), with clinically 
important but not statistically significant differences across reproductive groups 
(F[2,28] = 2.46, p =  .103, ηp2 = .150): early postmenopause, 38.3 kg/m2; 
perimenopause, 31.3 kg/m2; late postmenopause, 31.1 kg/m2. There were no 
significant differences in physical activity measures across the three reproductive 
groups at baseline (data not shown). 
3.4 Changes Between Baseline and Six Months 
3.4.1 Changes in neurocognitive scores. 
Within-person changes in neurocognitive function between baseline and 6 
months are presented in Table 4. Twenty-nine participants (64% of the initial sample) 
provided neurocognitive data at baseline and 6 months. Among those who completed 
both assessments, average scores on three of the four verbal learning subscales 
(immediate recall, long-term retrieval, consistent long-term retrieval) at 6 months 
were significantly better than scores at baseline (SRT-i, F[1,27] = 15.15, p = .001, ηp2 
= .359; SRT-lt, F[1,27] = 13.71, p = .001, ηp2 = .337; SRT-c, F[1,25] = 10.08, p = 
.004, ηp2 = .287). Participants also showed borderline significant improvement on the 
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Trails A task (F[1,25] = 3.54, p = .072, ηp2 = .124). No other notable six-month 
changes in neurocognitive performance were observed. 
Repeated-measures GLM tests revealed that reproductive stage was a 
significant predictor of six-month changes in normed verbal learning/memory 
subscales, including immediate verbal recall (SRT-i; F[2,20] = 6.42, p = .007, ηp2 = 
.391), long-term retrieval (SRT-lt; F[2,20] = 4.14, p = .031, ηp2 = .293), and 
consistent long-term retrieval (SRT-c; F[2,19] = 3.67, p = .045, ηp2 = .279), and 
verbal fluency (COWA; F[2,21] = 3.76, p = .042, ηp2 = .284). Post-hoc tests revealed 
that women in early postmenopause improved more than women in perimenopause (p 
= .048) on immediate verbal recall, while there were no significant differences in 
long-term retrieval, consistent long-term retrieval, or verbal fluency improvement 
between any two reproductive groups (see Figure 2). These effects remained 
significant after controlling for baseline age, BMI, depression, intellectual function 
(WTAR T scores), and reported insomnia: SRT-i, F[2,19] = 11.42, p = .001, ηp2 = 
.588; SRT-lt, F[2,10] = 6.85, p = .007, ηp2 = .461; SRT-c, F[2,18] = 7.28, p = .006, 
ηp
2 = .493; COWA, F[2,18] = 4.03, p = .040, ηp2 = .350. No other significant 
differences in neurocognitive change across groups were observed between baseline 
and 6 months.  
3.4.2 Subjective changes in memory and concentration. 
Almost half (44%) of participants reported (retrospectively) subjective 
improvement in concentration at 6 months, and 33% reported improvement in overall 
memory function. Mixed within-between person tests revealed that participants who 
reported improvement in concentration also had better verbal fluency (COWA) scores 
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at 6 months compared to baseline, while women who reported no improvement in 
concentration performed worse on verbal fluency at 6 months (F[1,25] = 10.11, p = 
.004, ηp2 = .288). Subjective improvement in concentration was not significantly 
associated with any other neurocognitive or physical activity measure. Subjective 
improvement in concentration was also not significantly different based on 
reproductive group.  
3.4.3 Subjective changes in menopausal symptoms. 
At 6 months, many participants noted retrospective improvements in the 
following menopause-related symptom domains: fatigue (44% of participants), hot 
flashes (26%), mood swings (26%), night sweats (26%), headaches (22%), and 
insomnia (22%). Additionally, 82% of participants reported improvement in overall 
health, 52% reported subjective improvement in mood, and 52% noted improvement 
in stress level at 6 months. Reported mood improvement was not significantly 
associated with within-person change in BDI-II score (data not shown).   
Compared to other reproductive groups, significantly more women in late 
postmenopause reported improvements in mood swings (Fisher’s Exact = 5.70, p = 
.026) and overall mood (Fisher’s Exact = 9.86, p = .006) since baseline. No other 
significant differences in menopause symptom change were observed across 
reproductive groups at 6 months. There was no significant association between 
reported improvements in hot flashes or night sweats and changes in neurocognitive 
function (data not shown). However, subjective improvement in mood at 6 months 
was significantly associated with improvement in verbal fluency (F[1,22] = 6.54, p = 
.018, ηp2 = .229). 
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3.4.4 Changes in physical activity. 
Twenty-six participants (68% of baseline sample) provided valid 
accelerometer data at 6 months. Participants engaged in an average of 305.07 
min/week (SD = 147.29), or about 45 min/day, of moderate-to-vigorous physical 
activity (MVPA) and 88.95 min/week (SD = 96.69), or about 12 min/day, of MVPA 
in bouts of 10 minutes or more (MVPA-10). Among program completers, MVPA at 6 
months was significantly higher than baseline MVPA (F[1,23] = 18.95, p < .001, ηp2 
= .452), and MVPA-10 at 6 months was significantly higher than baseline MVPA-10 
(F[1,23] = 7.24, p = .013, ηp2 = .239). Light activity at 6 months was 1,305.22 
min/week (SD = 591.88), or about 3 hr/day, and was also significantly greater than 
light activity at baseline (F[1,23] = 6.35, p = .020, ηp2 = .215). Sedentary activity at 6 
months was 4,290.84 min/week (SD = 1,383.60), or about 10 hr/day, and was not 
significantly different from baseline (F[1,23] = 2.39, p = .137, ηp2 = .094).   
Mixed design (within-between) tests revealed differences in six-month 
MVPA-10 changes across reproductive groups, with women in perimenopause 
showing significantly greater increases than women in early or late postmenopause 
(F[2,17] = 4.25, p = .032, ηp2 = .333). Reproductive stage did not significantly predict 
changes in any other physical activity measure: MVPA (F[2,17] = 2.57, p = .106, ηp2 
= .232), light activity (F[2,17] = .607, p = .556, ηp2 = .067), and sedentary activity 
(F[2,17] = .229, p = .798, ηp2 = .026). 
3.5 Change in Physical Activity Predicting Change in Neurocognitive Function 
Changes in physical activity (MVPA, MVPA-10, light activity, sedentary 
activity) between baseline and 6 months did not significantly predict changes in 
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neurocognitive function (Trails A, Trails B, Digit Span, SRT, COWA; See Table 5). 
Among program completers, MVPA at baseline also did not significantly predict six-
month changes in any neurocognitive domain (data not shown). However, among 
women in perimenopause (n = 7), six-month changes in light activity significantly 
and positively correlated with changes in normed COWA scores (r = .791, p = .034). 
In other words, increases in light activity were associated with improvements in 
verbal fluency, with scores pre-adjusted for differences in gender, age, education, and 
ethnicity. 
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CHAPTER 4: DISCUSSION 
The present study is the first known longitudinal examination of objective 
neurocognitive function in midlife women enrolled in a physical activity (PA) 
intervention program. Forty-five women age 40-63 years were recruited for a six-
month PA promotion program; assessments of neurocognitive function occurred at 
baseline and post-intervention (6 months). It was hypothesized that women in 
perimenopause (irregular menstruation to one year after the final menstrual period) 
would perform worse on tests of attention and working memory relative to women in 
postmenopause at baseline. While no significant differences in attention or working 
memory were observed across reproductive groups, women in early postmenopause 
demonstrated significantly poorer immediate verbal recall and long-term verbal 
retrieval at baseline. It was also hypothesized that improvements in cognitive function 
over the six-month intervention would be significantly correlated with increases in 
accelerometer-measured PA. The results did not show a significant association 
between physical activity and changes in neurocognitive function over the six-month 
intervention period. 
4.1 Prevalence of Menopausal Symptoms 
Vasomotor menopausal symptoms were prevalent in this sample, with 60% of 
women between perimenopause and late postmenopause experiencing hot flashes at 
some point in the prior six months, and 33% reporting night sweats at baseline. These 
data are approximately in line with the general population, where 15 to 52% of 
women in or around the menopause transition report hot flashes, and 14 to 42% report 
night sweats (Dennerstein, Dudley, Hopper, Guthrie, & Bruger, 2000). Such 
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thermoregulatory disruptions commonly peak in the two years following the final 
menstrual period (Nachtigall, L.E., & Nachtigall, M.J., 2004); this pattern, though not 
statistically significant, was observed in the present sample, where hot flashes were 
more common among women in perimenopause (46%) than participants in early 
postmenopause (23%) or late postmenopause (32%). Thus, the distribution of 
vasomotor symptoms in this study appears to reflect the experience of midlife women 
in the general population and may potentially be considered a valid clinical profile.   
Sleep disruptions, fatigue, mood changes, and headaches were endorsed by 
half to 70% of participants at baseline. While not all these symptoms are specific to 
menopause only, research indicates close associations between menopause-related 
vasomotor symptoms (e.g., hot flashes) and anxiety and stress, poorer quality of life, 
and fatigue from sleep deprivation or poor sleep quality (Utian, 2005). Accordingly, 
women in the present study who endorsed hot flashes at baseline were also more 
likely to report night sweats, sleep disturbances, and mood changes in the prior six 
months compared to women without hot flashes (p < .05). Interestingly, while recent 
mood changes were common in the present study sample, few participants (10%) met 
criteria for mild to severe depression based on self-report. This may highlight the 
qualitative difference between mood swings, which result from hormone fluctuations 
during the menopause transition, and clinical depression, which may be a more stable 
construct.  
4.2 Relation Between Neurocognitive Performance and Reproductive Stage  
Women in this study showed differential performance on an objective 
measure of verbal learning and memory, the Selective Reminding Test, based on their 
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reproductive stage at baseline; post-hoc comparisons revealed that women in early 
postmenopause scored significantly worse than both women in perimenopause (p = 
.010) and women in late postmenopause (p = .024). This finding makes theoretical 
sense in light of the hormone changes that to continue through early postmenopause; 
it is thought that changing estrogen levels may negatively impact the hippocampus 
and prefrontal cortex of the brain, and by extension impede executive function and 
verbal memory (Keenan et al., 2001). Furthermore, in the present study verbal 
memory differences could not be attributed to other clinical factors, such as sleep or 
mood. Thus, the differences observed in this study may be rooted in some cognitive 
or hormonal process specific to menopause.  
It is surprising, however, that participants in early postmenopause performed 
substantially worse than those in perimenopause. There are several possible 
explanations for this curiosity. First, about a third of early postmenopausal 
participants in this sample reported having their final menstrual periods within the 
previous two to three years, a stage marked by steep hormone fluctuations that 
parallel those of the perimenopausal period (Harlow et al., 2012). Given this 
biological overlap and the small sample size in the present study, it is possible that 
observed differences between perimenopause and early postmenopause were 
unreliable. Second, women who reported irregular periods (a hallmark symptom of 
perimenopause) were not asked to clarify whether the irregularity was typical of their 
normal menstrual cycle. Thus, it is possible that premenopausal women were 
incorrectly deemed perimenopausal, and such miscategorization could have resulted 
in artificially inflated (i.e., better) verbal memory scores in the perimenopause group. 
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Third, accurate group assignment may have been encumbered by nebulous 
menstruation data provided by some participants (e.g., final menstrual period was 
“over two years ago”). It is worth noting, however, that staging assignments did not 
change between baseline and 6 months, suggesting that participant report in this 
regard was sufficiently reliable (though not necessarily valid). Finally, verbal memory 
performance among early postmenopausal women was extremely low compared to 
norms. The extent of observed deficits is unexpected and may suggest the presence of 
some unanticipated factor driving the scores (i.e., misspecification error).  
Also in contrast to expectation, measures of attention and working memory 
did not significantly differ across reproductive stages at baseline. This may possibly 
be attributed to the measures employed in this study (Digit Span and Trail Making 
Tests A and B), which lack high diagnostic sensitivity. Indeed, previous research has 
also failed to uncover an association between menopause stage and performance on 
the Digit Span task (Weber, Rubin & Maki, 2013). Data from the Penn Letter N-back 
task, a more robust measure of attention, was affected by inconsistent systematic 
error2 and therefore could not be interpreted. It is also possible that verbal memory 
serves as a better proxy for cognitive disruption in this population than attention or 
other executive abilities. Future studies should work to clarify this matter, and 
identify neurocognitive measures that accurately and reliably reflect the biological 
underpinnings of menopause-related cognitive problems. 
 
                                                        
 
2 “Inconsistent systematic error” in this case refers to software malfunction. The Penn Letter n-back 
test stalled and failed to cycle through each test level on numerous occasions. Given the potential 
effects on recorded reaction times and lack of knowledge regarding which participants were affected, 
the data were deemed invalid.  
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4.3 Post-Intervention Neurocognitive Function and Physical Activity 
Following the six-month intervention, many participants (including those who 
denied problems with memory at baseline) reported retrospective improvements in 
memory (33%) and concentration (44%). Furthermore, objective verbal memory 
scores at 6 months were significantly better than baseline scores, particularly among 
women in early postmenopause, who effectively closed the verbal memory gap 
observed at baseline. Changes in neurocognitive function, however, did not 
significantly correlate with changes in moderate-to-vigorous physical activity. These 
findings suggest that something else occurring during the six-month intervention led 
to observed improvements. 
Interestingly, increases in light exercise, not moderate-to-vigorous activity 
(MVPA), were correlated with improvements in verbal fluency among women in 
perimenopause. These results intimate a potentially critical role for “lifestyle 
activity,” which is generally of low intensity (e.g., easy walking), to manage 
cognitive difficulties from menopause. Newer physical activity research has begun to 
explore the health benefits of light or lifestyle activity as a potentially easier target for 
intervention than effortful aerobic exercise. While this subject remains controversial, 
research has shown that replacing just 30 minutes of sedentary activity with light 
activity confers similar health benefits as those observed from MVPA (Buman et al., 
2010). Moreover, light activity has been associated with more psychosocial benefits, 
including greater life satisfaction and lower perceived stress, than MVPA (Buman et 
al., 2010).  
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It is also possible that the impact of exercise in this sample occurred 
indirectly, via improvements in overall health, mood, or vasomotor menopause 
symptoms. However, no clear connections between alterations in menopausal 
symptoms and changes in any neurocognitive or physical activity measure at 6 
months were observed, and only about a quarter of women reported six-month 
improvements in the frequency or intensity of hot flashes, mood swings, night sweats 
or insomnia. Most women (82%) noted improvement in overall health; however, it is 
difficult to determine the specific meaning(s) of such of such changes without further 
clarification from participants or an objective physical health measure (e.g., lipid 
levels). It is possible that improvements in diet or cardiovascular fitness that were 
reflected in changes in weight, physical activity, or menopausal symptoms drove the 
observed neurocognitive changes. Overall, the present study findings align with the 
larger literature base demonstrating positive effects on cognitive function from 
physical activity and, in this case, light or lifestyle activity (Kramer & Erickson, 
2007; Larson et al., 2006; Weuve et al., 2004).   
4.4 Limitations 
 This study was primarily limited by small sample size and moderate attrition; 
changes in funding for the parent pilot study precluded continuation of recruitment 
efforts to achieve the intended participant number. This effectively limited analytic 
power, disallowing inclusion of premenopausal participants or finer division of the 
perimenopause group into early and late perimenopause. The small sample size also 
increased the probability of other potentially important factors, such as use of 
psychotropic medications and history of learning disability, skewing the results. 
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Moreover, the number of analyses presented in this study was not sufficiently 
supported by power analyses. A large sample size would facilitate sophisticated 
statistical analyses within groups and provide a more accurate representation of the 
biological underpinnings of these groupings. Additionally, it is unknown whether data 
from participant dropouts at 6 months would have changed the results. Post-hoc 
analyses revealed no significant demographic or neurocognitive differences between 
those who completed the study and those who did not, and no notable differences in 
self-reported menopause symptoms. While completers had significantly higher 
baseline levels of moderate-to-vigorous aerobic activity and better sleep quality, there 
is no obvious reason why these differences would have altered the study findings.   
 In addition, key measures of attention and working memory employed in the 
present study may not have detected small cross-sectional differences or changes over 
the six-month intervention. Future studies should employ more sensitive assessment 
techniques, such as the Letter N-back test initially intended for the present study. 
Alternatively, the known ceiling effect that restricts the sensitivity of the Trail 
Making Test and Digit Span subtest may be less prominent among lower functioning 
participants; recruiting individuals with objective deficits might address this barrier. 
Reliance on self-report to assess sleep quality is also an inferior method (Lauderdale 
et al., 2008); wrist actigraphy may be used in future studies for greater accuracy. 
Finally, the present sample consisted of treatment-seeking participants who 
may not be representative of the general population of midlife women. While a range 
of cognitive abilities and BMI were represented, data from non-treatment seeking 
females may have differed at baseline or over time. Random selection of potential 
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participants through mechanisms such as primary care offices may be beneficial in 
this regard. In addition, future studies may choose to include a non-exercise control 
group.  
4.5 Conclusions and Future Directions 
 Despite the aforementioned limitations, this study adds to the literature by 
providing evidence of objective neurocognitive differences across women in different 
reproductive stages, in addition to illustrating a potentially positive effect of light or 
lifestyle activity on verbal ability. Postmenopausal participants were divided into two 
groups, early and late postmenopause, which has been done in few studies; such 
distinction is important, given the dramatic changes in menopausal symptoms and 
gonadal hormone levels occurring between early and late postmenopause. Indeed, the 
present study found substantial differences in verbal abilities between postmenopause 
groups. Future research should acknowledge this distinction and plan study 
recruitment accordingly.   
In addition to neurocognitive testing, future research should track hormone 
fluctuations with blood draws (e.g., several per day for multiple days) at each 
assessment point. The prevailing evidence suggests that abrupt changes (as opposed 
to absolute values) in estrogen and follicle stimulating hormone (FSH) levels are 
responsible for the cognitive disruptions observed during the menopause years. 
Measurements taken over the multiple days would produce a more accurate picture of 
daily vacillations. Finally, participants should be followed post-intervention to assess 
whether the influence of physical activity is lasting or dependent on continued 
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exercise, and to clarify the distinct contributions of light versus moderate-to-vigorous 
activity.   
Based on the present study data, clinicians should be aware that verbal 
memory problems may persist beyond the menopause transition, and women should 
be warned about potential verbal memory deficits. While the effect of aerobic 
physical activity on cognitive function in this population remains unclear, the data 
provide early support for lifestyle activity as way to manage bothersome menopausal 
symptoms, including cognitive disruption. Furthermore, the vascular and other risk 
factors characterizing the menopause years necessitate attention to diet and healthy 
lifestyle choices. 
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Appendix A: Tables 
 
 
 
Table 1: Participant characteristics at baseline (N = 45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable  
Mean ± SD 
 
Range 
Age (yrs) 53.6 ± 6.6 40 - 63 
Highest education completed (yrs) 15.7 ± 1.6 12 - 18 
BMI (kg/m2) 32.7 ± 7.3 20.8 – 50.3 
Depression score (BDI-II)  7.0 ± 5.7 0 - 30 
Sleep quality score (PSQI) 6.0 ± 2.3 2 -13 
   
 n % 
Race   
    Caucasian 30 66.7 
    Black/African American 13 28.9 
    Hispanic/Latina 1 2.2 
    Asian 1 2.2 
Married 23 51.1 
Children (yes) 32 71.1 
Reproductive stage   
    Premenopause 3 7.5 
    Perimenopause 14 35.0 
    Early postmenopause 10 25.0 
    Late postmenopause 13 32.5 
Menopause symptoms (past 6 mo)   
    Sleep problems 30 69.8 
    Fatigue 29 64.4 
    Hot flashes 27 61.4 
    Mood changes 21 51.2 
    Headaches 20 47.6 
    Night sweats 17 38.6 
Hormone treatment   
    Current 1 2.2 
    Past 5 11.1 
Infertility/miscarriage history 11 24.4 
Current smoker 1 2.2 
        53 
 
 
 
 
Table 2: Neurocognitive scores in full sample and by reproductive group at baseline 
 
Perimenopause  
(n = 14) 
Early Postmenopause  
(n = 10) 
Late Postmenopause  
(n = 13)    
Variable Raw score a T score Raw score a T score Raw score a T score F b p b ηp2 
Global cognitive function  (MoCA) 27.3 ± 1.89 59.6 ± 5.1 25.9 ± 3.1 54.4 ± 8.4 26.3 ± 1.1 56.1 ± 6.8 1.89 .166 .103 
Intellectual function (WTAR) 38.1 ± 8.78 57.1 ± 6.5 39.8 ± 9.3 58.1 ± 7.3 41.3 ± 4.7 59.1 ± 5.0 0.31 .733 .019 
Attention/Executive function (Trails A) 27.5 ± 12.1 56.2 ± 7.0 31.8 ± 13.7 50.6 ± 7.6 29.9 ± 11.2 50.8 ± 11.2 1.36 .272 .086 
Attention/Executive function (Trails B) 64.9 ± 28.2 54.8 ± 10.2 72.0 ± 26.4 49.0 ± 6.9 71.2 ± 22.4 51.8 ± 10.0 0.96 .393 .060 
Attention/Working memory (Digit Span) 28.7 ± 7.0 50.6 ± 8.7 26.8 ± 5.7 50.3 ± 11.1 26.9 ± 5.6 49.2 ± 8.5 0.07 .931 .004 
 
Verbal learning – immediate  (SRT-i) 45.4 ± 8.5 37.5 ± 13.1 37.6 ± 9.7 25.7 ± 14.8 45.1 ± 6.5 40.7 ± 10.8 3.93 .029 .193 
Verbal learning – delayed  (SRT-d) c 8.08 ± 2.06 -- 6.90 ± 3.11 -- 7.58 ± 2.71 -- 0.57 .570 .035 
 
Verbal fluency (COWA) 44.9 ± 10.2 52.8 ± 10.1 44.7 ± 11.7 53.1 ± 10.8 45.5 ± 11.7 51.3 ± 9.9 0.10 .904 .006 
          
a Raw scores include outliers 
b GLM across reproductive groups using T scores 
c GLM analyses performed on raw data due to lack of appropriate norms 
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Table 3: Pearson’s r correlations at baseline (N = 45) a 
Variable MoCAa WTARa Trails Aa Trails B a Digit Span a SRT-i a 
 
SRT-d b COWAa 
BMI -.384 -.544 -.184 -.223 -.108 -.252 -.128 -.096 
(p-value) (.019) (.001) (.297) (.206) (.520) (.132) (.450) (.583) 
Depression (BDI) -.040 .131 .285 .014 -.075 .021 -.034 -.176 
(p-value) (.808) (.432) (.092)* (.936) (.649) (.899) (.839) (.297) 
Sleep Quality (PSQI) -.045 -.131 .061 -.075 -.346 -.046 .004 -.187 
     (p-value) (.819) (.516) (.769) (.704) (.077)* (.823) (.984) (.349) 
MVPA total  .280 .363 .341 .251 .153 .087 .099 .076 
(p-value) (.093)* (.030) (.049) (.152) (.360) (.607) (.559) (.663) 
MVPA-10 c -.140 -.188 -.220 -.216 -.105 -.189 -.353 -.032  
(p-value) (.513) (.378) (.324) (.334) (.626) (.376) (.099)* (.888) 
Light activity  .098 .231 .576 .301 -.005 .046 .080 -.012 
(p-value) (.565) (.175) (< .001) (.084)* (.978) (.786) (.638) (.943) 
Sedentary activity  .155 .201  .279 .153 .010 .115 .229 .160 
(p-value) (.359) (.239) (.110) (.389) (.952) (.499) (.172) (.358) 
a Correlations based on T scores normed for age, education, race, and/or gender, and removed of extreme outliers (where applicable) 
b Correlations based on normalized raw values 
c MVPA-10 T score removed of outliers and log-transformed 
* Borderline/trend (p < .10) 
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Table 4: Neurocognitive scores among program completers at baseline and 6 months a 
 
 
Baseline                              6 Months   
 
Variable Raw score T score Raw score T score F a p a  ηp2 
Attention/Executive function (Trails A) 30.1 ± 12.9 50.4 ± 11.5 26.1 ± 7.9 53.7 ± 9.5 3.54 .072 .124 
Attention/Executive function (Trails B) 65.5 ± 26.0 53.3 ± 10.6 63.1 ± 24.0 53.9 ± 11.1 0.36 .555 .013 
Attention/Working memory (Digit Span) 27.5 ± 5.2 51.3 ± 8.9 28.1 ± 4.8 51.9 ± 9.3 0.84 .366 .029 
Verbal learning – immediate recall (SRT-i) 45.1 ± 9.1 39.6 ± 13.1 51.1 ± 8.5 48.3 ± 12.1 15.15 .001 .359 
Verbal learning – delayed recall (SRT-d) 8.4 ± 2.8 -- 9.1 ± 2.8 -- 3.34 .079 .110 
Verbal fluency (COWA) 47.0 ± 12.3 52.9 ± 10.8 48.2 ± 12.8 53.6 ± 10.8 0.69 .414 .025 
a Repeated-measures GLM analyses calculated on raw values
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Table 5: Change in physical activity predicting change in neurocognitive T scoresa 
Dependent Variable Independent Variable F  p   ηp
2 
Attention/Executive function (Trails A)      
 MVPA total change 0.37 .548 .017 
 MVPA 10-min bouts change 0.43 .517 .020 
 Light activity change 0.98 .334 .044 
 Sedentary activity change 0.84 .371 .038 
Attention/Executive function (Trails B)      
 MVPA total change 0.99 .331 .045 
 MVPA in 10-min bouts change 0.81 .379 .037 
 Light activity change 0.17 .684 .008 
 Sedentary activity change 0.61 .443 .028 
Attention/Working memory (Digit Span)      
 MVPA total change 0.14 .711 .007 
 MVPA in 10-min bouts change 0.02 .905 .001 
 Light activity change 0.03 .860 .002 
 Sedentary activity change 1.39 .252 .065 
Verbal learning – immediate recall (SRT-i)     
 MVPA total change 2.33 .142 .100 
 MVPA in 10-min bouts change 0.74 .401 .034 
 Light activity change < 0.01 .993 < .001 
 Sedentary activity change 0.25 .619 .011 
Verbal learning – delayed recall (SRT-d)     
 MVPA total change .011 .918 .001 
 MVPA in 10-min bouts change .163 .690 .008 
 Light activity change .017 .897 .001 
 Sedentary activity change 2.88 .103 .111 
Verbal fluency (COWA FAS)      
 MVPA total change 0.05 .834 .002 
 MVPA in 10-min bouts change 1.01 .326 .044 
 Light activity change 0.05 .821 .002 
 Sedentary activity change 0.35 .563 .015 
a Repeated-Measures GLM regression
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Figure 1: Recruitment flow diagram
Completed Pre-Baseline 
Surveys 
(N = 59) 
Completed Baseline 
Assessment  
(n = 45) 
Initiated Intervention  
(n = 38) 
Ineligible or lost to follow-up 
(n = 15) 
 
 
Accelerometer invalid or ineligible         
(n = 7) 
 
Completed Intervention 
(n = 26) 
 
Dropped or lost to follow-up (n = 10) 
Accelerometer invalid or missing (n = 2) 
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 Figure 2: Change in verbal learning (SRT-i) by reproductive group 
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SPECIAL SKILLS                 
• Computer: SAS, SPSS, Microsoft Office suite 
• Evidence-Based Treatments: Cognitive Behavioral Therapy (CBT-D, CBT-I), 
Cognitive Processing Therapy, Motivational Interviewing, Prolonged Exposure
   
 
 
